COPD is characterized by respiratory symptoms due to abnormalities of the airways or alveoli that cause persistent airflow obstruction.
Globally COPD is estimated to affect 10.3% of adults age 25 years or older and exacerbation are defined as episodes of increased dyspnea and/or cough.
Stable COPD is defined as COPD not in active exacerbation: the goals of treatment are symptom and exacerbation risk reduction.
The initial inhaled pharmacotherapy for stable COPD is based on symptoms and exacerbation frequency.
All patients with COPD should be offered a short acting bronchodilator for immediate symptomatic relief.
For patients with mild symptoms and infrequent exacerbations, (GOLD group A), monotherapy with a long-acting bronchodilator is suggested over a short acting bronchodilators as initial therapy.
For patients with more symptoms (GOLD group B) or frequent exacerbations (GOLD group, E), a long acting beta2 agonist, with a long acting muscarinic antagonist are recommended as initial therapy.
For patients experiencing one or more exacerbations per year, despite proper use of combined long acting beta2 agonist-long acting muscarinic antagonist regimen, the addition of inhaled corticosteroids is recommended as escalation therapy if blood eosinophil count is 100 µg per liter or higher.
Long-acting bronchodilators are recommended as the primary maintenance inhalant therapy for stable chronic obstructive pulmonary disease (COPD).
Among these, long-acting muscarinic antagonists (LAMAs) are preferred as first-line monotherapy because they more effectively reduce exacerbations and hospitalizations compared to long-acting beta agonists (LABAs), and are associated with fewer adverse events.
No specific LAMA formulation is favored over another.
If symptoms persist despite LAMA monotherapy, the guidelines suggest considering the addition of a LABA.
Inhaled corticosteroid (ICS) monotherapy is not recommended due to lower efficacy and increased risk of adverse effects, such as candidiasis, hoarseness, and pneumonia.
ICS should only be added to LABA/LAMA therapy in patients with frequent exacerbations, as this combination further reduces exacerbation risk but increases pneumonia risk.
Long-acting bronchodilators improve dyspnea, reduce exacerbations, and enhance quality of life, with LAMAs demonstrating superior outcomes in preventing exacerbations and hospitalizations compared to LABAs or ICS/LABA combinations.
Large randomized trials such as INVIGORATE and POET-COPD have demonstrated that long-acting muscarinic antagonists (LAMAs), such as tiotropium, reduce exacerbation rates more effectively than long-acting beta2-agonists (LABAs) alone, though both classes improve lung function and symptoms with similar safety profiles.
For patients with persistent symptoms or frequent exacerbations, dual bronchodilator therapy with a LABA-LAMA combination provides additional benefit in lung function and symptom control compared to monotherapy, as supported by network meta-analyses and recent GOLD recommendations.
The addition of inhaled corticosteroids (ICS) to dual bronchodilator therapy (LABA-LAMA-ICS, or triple therapy) is reserved for patients with a history of frequent exacerbations, particularly those with elevated blood eosinophil counts, as this approach further reduces exacerbation risk and may lower mortality, but at the cost of increased pneumonia risk.
ICS monotherapy is not recommended due to inferior efficacy and increased adverse events.